Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.
Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.
Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.
Alessa Therapeutics, Inc. is a pre-clinical stage company based in San Francisco, California, focused on developing localized treatments for solid organ diseases, particularly prostate cancer. Founded in 2018, the company specializes in a drug delivery implantable system that administers anti-androgen drugs directly to prostate tumors. This innovative system allows for sustained and localized treatment, minimizing systemic exposure and enhancing the efficacy of therapy for patients. By concentrating on specific organ diseases, Alessa Therapeutics aims to improve treatment outcomes and quality of life for patients suffering from these conditions.
Tangible Science, LLC specializes in the development of innovative products aimed at enhancing the comfort of contact lens users, particularly those suffering from dry eye conditions. Founded in 2011 and based in Redwood City, California, the company has created a polymer coating technology that provides a bio-compatible and highly hydrated surface for contact lenses. This technology helps maintain the natural tear film, significantly reducing discomfort associated with lens wear. Tangible Science's product offerings include contact lens coatings, cleaners, rejuvenators, and a line of disposable lenses, all designed to improve the overall experience for patients, eye care professionals, and contact lens manufacturers.
Photoswitch Biosciences, Inc. is a biotechnology company based in Menlo Park, California, founded in 2008. The company specializes in developing innovative tools for drug screening and safety pharmacology studies, focusing on excitable membrane biology. It manufactures instruments that control the function of ion channels and offers optical kinetic plate readers and voltage-sensitive dyeing devices. These products enable the assay of electrical properties in induced pluripotent stem cell cardiomyocytes, whether in a spontaneously active or optically paced state. By utilizing channelrhodopsin-based optical control, Photoswitch Biosciences simplifies the screening and testing of new drug candidates, providing valuable resources for biotechnology researchers.
QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.
Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.
Cereius, Inc. is a privately owned, pre-clinical stage company based in Durham, North Carolina, focused on developing innovative small-molecule therapies for treating brain metastasis specifically in patients with HER2-positive breast cancer. Established in 2017, the company employs novel radiolabeling chemistries that improve the uptake and retention of radionuclides in targeted tumors while reducing uptake in normal tissues. This approach aims to significantly enhance both the therapeutic index and diagnostic contrast of targeting agents, positioning Cereius as a key player in the advancement of treatment options for solid tumor brain metastasis.
ViewPoint Therapeutics, a biotechnology company founded in 2014 and based in San Francisco, focuses on developing treatments for diseases caused by protein misfolding, particularly cataracts. The company is advancing its research on crystallin stabilizers, which are small molecules designed to prevent and treat age-related cataracts and presbyopia. These stabilizers have shown promise in preclinical models through a systematic screening and optimization process. By targeting protein misfolding, ViewPoint Therapeutics aims to provide effective therapies for common age-related disorders, including cataracts and neurodegenerative diseases, ultimately enhancing treatment options for physicians and their patients.
Epiodyne, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative drugs that target the delta opioid receptors and the brain's opioid peptide system. Established in 2016, Epiodyne aims to create novel analgesics to address neurobehavioral symptoms associated with brain disorders, particularly for patients suffering from opioid use disorder. The company's research is centered on restoring the brain's reward system to effectively treat issues related to compulsivity, self-injury, and addiction, thereby providing new therapeutic options for individuals in need of effective treatment solutions.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.
Redwood Bioscience specializes in precision protein-chemical engineering to create optimized biotherapeutics. The company employs site-specific modification technology, which addresses the challenges of conjugating biologics with synthetic molecules, resulting in homogeneous hybrid biotherapeutics. These hybrid drugs combine the specificity and extended half-life of biologics with the potency of synthetic peptides and small molecules. By utilizing modified carrier scaffolds, Redwood develops peptide therapeutics aimed at enhancing serum half-lives and antibody-drug conjugates that exhibit improved potency and reduced toxicity. Additionally, the company is expanding the chemical space of protein drugs by creating heterofunctional products with unique architectures. Redwood collaborates with partners to enhance the value of existing programs and to jointly develop innovative compounds while also pursuing its own internal biotherapeutic programs.
Symic Biomedical, based in San Francisco, California, is a biotechnology company focused on developing matrix regulator therapeutics to address various health conditions. Founded in 2012, the company aims to treat osteoarthritis and cardiovascular diseases by targeting and inhibiting matrix degradation and pathological inflammatory responses associated with injury and disease. Its therapeutics are designed to bind to specific targets within the extracellular matrix, presenting potential applications in fibrosis, oncology, and central nervous system disorders. As a subsidiary of Symic Holdings, LLC, Symic Biomedical is dedicated to advancing therapeutic solutions that can improve patient outcomes in these critical areas of healthcare.
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, focused on developing cell-permeable macrocyclic peptide therapeutics. Founded in 2012 by Professors Matt Jacobson and Scott Lokey, the company utilizes proprietary computational design algorithms and innovative synthetic chemistry to create macrocycles targeting significant clinical challenges. Their approach involves an iterative design process that leverages large virtual libraries of diverse macrocycle scaffolds, selected for their permeability. Circle Pharma aims to address unmet clinical needs, particularly in the treatment of cancer, by focusing on intracellular protein-protein interactions through its novel macrocycle therapies, which can be delivered via multiple routes, including oral administration. The company's work is intended to enable healthcare professionals to advance internal development efforts in this critical area of medicine.
iPierian is engaged in the research and development of therapies aimed at treating neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. The company utilizes induced pluripotent stem cells to facilitate drug discovery and development, focusing on addressing significant unmet medical needs. In particular, iPierian is developing therapies and monoclonal antibodies that target Tauopathies, which are diseases characterized by the accumulation of tau protein in the brain. These therapies aim to slow the spread of tau throughout the brain, thereby inhibiting the progression of associated diseases.